Search results
Showing 501 to 550 of 646 results for diabetes
Community based approaches to addressing high blood pressure with black African and Caribbean men
ethnicity in developing cardiovascular disease, linked to a higher risk of diabetes and hypertension in South Asian, Black African or...
Macimorelin for diagnosing growth hormone deficiency (MIB320)
NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .
Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)
NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.
metabolic (including weight gain and diabetes) extrapyramidal (including akathisia
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
VEST external stent for coronary artery bypass grafts (MIB115)
NICE has developed a medtech innovation briefing (MIB) on the VEST external stent for coronary artery bypass grafts .
with interrelated long-term conditions and themes include kidney care, diabetes, neurological conditions and rehabilitation. The...
This evidence summary has been updated and replaced by NICE advice ESNM24.
This evidence summary has been updated and replaced by NICE advice ESNM25.
This evidence summary has been updated and replaced by NICE guideline NG17.
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
person's risk of complications (possibly because of comorbidities, such as diabetes or immunosuppression) and any previous antibiotic...
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults.
This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).
Health app: GDm-Health for people with gestational diabetes (MIB131)
This health app briefing on GDm-Health for people with gestational diabetes has been withdrawn.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please go to NICE interventional procedure guidance 257 to view the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE interventional procedure guidance 274 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.
Liraglutide for the treatment of type 2 diabetes mellitus (TA203)
This guidance has been updated and replaced by NICE guideline NG28.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
Guidance on the use of patient-education models for diabetes (TA60)
This guidance has been replaced by NICE guideline NG17.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
Mental health of adults in contact with the criminal justice system (NG66)
This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.
View recommendations for NG66Show all sections
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .
Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)
This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.
In development [GID-MT538] Expected publication date: TBC
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)
This evidence summary has been updated and replaced by NICE guideline NG17.
This quality standard covers prevention of falls and assessment after a fall in older people (aged 65 and over) who are living in the community or staying in hospital. It describes high-quality care in priority areas for improvement.
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Identifying people at risk of falling
- Quality statement 2: Multifactorial risk assessment for older people at risk of falling
- Quality statement 3: Multifactorial intervention
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
This guidance has been replaced by NICE guideline NG17.